Forte Biosciences, Inc.FBRXNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 74.61% |
| Q2 2025 | -31.28% |
| Q1 2025 | 139.81% |
| Q4 2024 | -8.57% |
| Q3 2024 | -0.35% |
| Q2 2024 | 31.86% |
| Q1 2024 | 22.04% |
| Q4 2023 | -43.99% |
| Q3 2023 | -10.79% |
| Q2 2023 | 49.13% |
| Q1 2023 | 92.40% |
| Q4 2022 | 80.42% |
| Q3 2022 | 33.37% |
| Q2 2022 | 49.21% |
| Q1 2022 | -48.74% |
| Q4 2021 | -76.06% |
| Q3 2021 | 60.29% |
| Q2 2021 | 6.05% |
| Q1 2021 | 9.82% |
| Q4 2020 | -17.98% |
| Q3 2020 | 90.40% |
| Q2 2020 | 43.06% |
| Q1 2020 | -82.17% |
| Q4 2019 | 2051.84% |
| Q3 2019 | 13.87% |
| Q2 2019 | -64.08% |
| Q1 2019 | -94.47% |
| Q4 2018 | 27.38% |
| Q3 2018 | -3.93% |
| Q2 2018 | 22.30% |
| Q1 2018 | 25.83% |
| Q4 2017 | 9.67% |
| Q3 2017 | 14.04% |
| Q2 2017 | 0.12% |
| Q1 2017 | 0.00% |